These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 27354019)

  • 1. Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
    Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X
    Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
    Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
    Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
    J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
    AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R
    J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of grey matter atrophy between patients with neuromyelitis optica and multiple sclerosis: a voxel-based morphometry study.
    Duan Y; Liu Y; Liang P; Jia X; Yu C; Qin W; Sun H; Liao Z; Ye J; Li K
    Eur J Radiol; 2012 Feb; 81(2):e110-4. PubMed ID: 21316170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of global and regional gray matter volume decrease in multiple sclerosis.
    Grothe M; Lotze M; Langner S; Dressel A
    J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis.
    Sastre-Garriga J; Arévalo MJ; Renom M; Alonso J; González I; Galán I; Montalban X; Rovira A
    J Neurol Sci; 2009 Jul; 282(1-2):120-4. PubMed ID: 19157420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep gray matter volume loss drives disability worsening in multiple sclerosis.
    Eshaghi A; Prados F; Brownlee WJ; Altmann DR; Tur C; Cardoso MJ; De Angelis F; van de Pavert SH; Cawley N; De Stefano N; Stromillo ML; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Vrenken H; Leurs CE; Killestein J; Pirpamer L; Enzinger C; Ourselin S; Wheeler-Kingshott CAMG; Chard D; Thompson AJ; Alexander DC; Barkhof F; Ciccarelli O;
    Ann Neurol; 2018 Feb; 83(2):210-222. PubMed ID: 29331092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
    Koskimäki F; Bernard J; Yong J; Arndt N; Carroll T; Lee SK; Reder AT; Javed A
    PLoS One; 2018; 13(12):e0209326. PubMed ID: 30576361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study.
    Galego O; Gouveia A; Batista S; Moura C; Machado E
    Neuroradiol J; 2015 Jun; 28(3):354-8. PubMed ID: 26246109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.
    Vidal-Jordana A; Sastre-Garriga J; Pérez-Miralles F; Tur C; Tintoré M; Horga A; Auger C; Río J; Nos C; Edo MC; Arévalo MJ; Castilló J; Rovira A; Montalban X
    Mult Scler; 2013 Aug; 19(9):1175-81. PubMed ID: 23319072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines.
    Chu R; Kim G; Tauhid S; Khalid F; Healy BC; Bakshi R
    PLoS One; 2018; 13(11):e0206939. PubMed ID: 30408094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
    Fisher E; Nakamura K; Lee JC; You X; Sperling B; Rudick RA
    Mult Scler; 2016 Apr; 22(5):668-76. PubMed ID: 26238463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
    Sotirchos ES; Gonzalez-Caldito N; Dewey BE; Fitzgerald KC; Glaister J; Filippatou A; Ogbuokiri E; Feldman S; Kwakyi O; Risher H; Crainiceanu C; Pham DL; Van Zijl PC; Mowry EM; Reich DS; Prince JL; Calabresi PA; Saidha S
    Mult Scler; 2020 Mar; 26(3):312-321. PubMed ID: 30741108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis.
    Meijboom R; York EN; Kampaite A; Harris MA; White N; Valdés Hernández MDC; Thrippleton MJ; MacDougall NJJ; Connick P; Hunt DPJ; Chandran S; Waldman AD;
    PLoS One; 2023; 18(7):e0288967. PubMed ID: 37506096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates.
    Rekik A; Aissi M; Rekik I; Mhiri M; Frih MA
    Brain Behav; 2022 May; 12(5):e2573. PubMed ID: 35398999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of early brain atrophy in clinically isolated syndromes.
    Pérez-Miralles F; Sastre-Garriga J; Tintoré M; Arrambide G; Nos C; Perkal H; Río J; Edo MC; Horga A; Castilló J; Auger C; Huerga E; Rovira A; Montalban X
    Mult Scler; 2013 Dec; 19(14):1878-86. PubMed ID: 23652215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant.
    Steenwijk MD; Geurts JJ; Daams M; Tijms BM; Wink AM; Balk LJ; Tewarie PK; Uitdehaag BM; Barkhof F; Vrenken H; Pouwels PJ
    Brain; 2016 Jan; 139(Pt 1):115-26. PubMed ID: 26637488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global and regional annual brain volume loss rates in physiological aging.
    Schippling S; Ostwaldt AC; Suppa P; Spies L; Manogaran P; Gocke C; Huppertz HJ; Opfer R
    J Neurol; 2017 Mar; 264(3):520-528. PubMed ID: 28054131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.